{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T20:05:17Z","timestamp":1793390717500,"version":"4.5.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T00:00:00Z","timestamp":1744675200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The complement system is a key component of the innate immune system. In antiacetylcholine receptor (AChR) antibody-positive (Ab+) generalized myasthenia gravis (MG), complement activation has long been considered a principal driver of pathology. Understanding the role of complement in AChR-Ab+ generalized MG has gained increasing importance in recent years, as anticomplement drugs have been approved for clinical use or are undergoing phase II\/III clinical trials. This review aims to discuss recent and previous findings on the role of complement in AChR-Ab+ MG pathology, including its interaction with pathogenic antibodies and mechanisms beyond the classical pathway activation.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1526317","type":"journal-article","created":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:20:02Z","timestamp":1744694402000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["The role of complement in the immunopathogenesis of acetylcholine receptor antibody-positive generalized myasthenia gravis: bystander or key player?"],"prefix":"10.3389","volume":"16","author":[{"given":"Iliana","family":"Michailidou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Patsiarika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evangelia","family":"Kesidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina Kleopatra","family":"Boziki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Parisis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos","family":"Bakirtzis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Chroni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Grigoriadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.52.10.1121","article-title":"The natural course of myasthenia gravis: a long term follow up study","volume":"52","author":"Oosterhuis","year":"1989","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.05.023","article-title":"Prognosis of ocular myasthenia in Korea: a retrospective multicenter analysis of 202 patients","volume":"273","author":"Hong","year":"2008","journal-title":"J Neurol Sci"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI29894","article-title":"Myasthenia gravis: past, present, and future","volume":"116","author":"Conti-Fine","year":"2006","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"Vincent","year":"2001","journal-title":"Lancet"},{"key":"B6","article-title":"Acetylcholine receptor antibody in myasthenia gravis: predominance of IgG subclasses 1 and 3","volume":"67","author":"R\u00f8dgaard","year":"1987","journal-title":"Clin Exp Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2008.01.013","article-title":"Clinical fluctuations in MuSK myasthenia gravis are related to antigen-specific IgG4 instead of IgG1","volume":"195","author":"Niks","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B8","article-title":"Inhibition of complement activation by IgG4 antibodies","volume":"64","author":"van der Zee","year":"1986","journal-title":"Clin Exp Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13522","article-title":"Myasthenia gravis: the role of complement at the neuromuscular junction","volume":"1412","author":"Howard","year":"2018","journal-title":"Ann New York Acad Sci"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis","volume":"30","author":"Stascheit","year":"2023","journal-title":"Eur J Neurol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"120494","DOI":"10.1016\/j.jns.2022.120494","article-title":"Motor end-plate analysis to diagnose immune-mediated myasthenia gravis in seronegative patients","volume":"443","author":"Nagaoka","year":"2022","journal-title":"J Neurological Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00917\/full","article-title":"Complement inhibitor therapy for myasthenia gravis","volume":"11","author":"Albazli","year":"2020","journal-title":"Front Immunol"},{"key":"B14","first-page":"201","article-title":"How myasthenia gravis alters the safety factor for neuromuscular transmission","volume":"201","author":"Ruff","year":"2008","journal-title":"J Neuroimmunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24398","article-title":"Complement C1q-C3-associated synaptic changes in multiple sclerosis hippocampus","volume":"77","author":"Michailidou","year":"2015","journal-title":"Ann Neurol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.10.036","article-title":"The classical complement cascade mediates CNS synapse elimination","volume":"131","author":"Stevens","year":"2007","journal-title":"Cell"},{"key":"B17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-065X.1998.tb01190.x","article-title":"Anatomy of the antigenic structure of a large membrane autoantigen, the muscle-type nicotinic acetylcholine receptor","volume":"163","author":"Tzartos","year":"1998","journal-title":"Immunol Rev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"671","DOI":"10.3390\/cells8070671","article-title":"Myasthenia gravis: pathogenic effects of autoantibodies on neuromuscular architecture","volume":"8","author":"Koneczny","year":"2019","journal-title":"Cells"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.186.4158.55","article-title":"Serum globulin in myasthenia gravis: inhibition of alpha-bungarotoxin binding to acetylcholine receptors","volume":"186","author":"Almon","year":"1974","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/39.10.2053","article-title":"Detection and characterization of blocking-type anti-acetylcholine receptor antibodies in sera from patients with myasthenia gravis","volume":"39","author":"Hara","year":"1993","journal-title":"Clin Chem"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410440412","article-title":"Acquired slow-channel syndrome: a form of myasthenia gravis with prolonged open time of the acetylcholine receptor channel","volume":"44","author":"Wintzen","year":"1998","journal-title":"Ann Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.9.1497","article-title":"Inflammation at the neuromuscular junction in myasthenia gravis","volume":"41","author":"Maselli","year":"1991","journal-title":"Neurology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1981.tb33741.x","article-title":"Humoral immunity in myasthenia gravis: clinical correlations of anti-receptor antibody avidity and titer","volume":"377","author":"Tindall","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/0165-5728(86)90098-6","article-title":"Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis","volume":"12","author":"Vernet-der Garabedian","year":"1986","journal-title":"J Neuroimmunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198209233071301","article-title":"Functional activities of autoantibodies to acetylcholine receptors and the clinical severity of myasthenia gravis","volume":"307","author":"Drachman","year":"1982","journal-title":"N Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.33.10.1316","article-title":"Myasthenia gravis: long-term correlation of binding and bungarotoxin blocking antibodies against acetylcholine receptors with changes in disease severity","volume":"33","author":"Besinger","year":"1983","journal-title":"Neurology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-015-2236-8","article-title":"Both binding and blocking antibodies correlate with disease severity in myasthenia gravis","volume":"36","author":"Kang","year":"2015","journal-title":"Neurol Sci"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.136.9.3231","article-title":"Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate","volume":"136","author":"Tzartos","year":"1986","journal-title":"J Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198211000-00001","article-title":"Ultrastructural aspects of acetylcholine receptor turnover at the normal end-plate and in autoimmune myasthenia gravis","volume":"41","author":"Fumagalli","year":"1982","journal-title":"J Neuropathol Exp Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.46.5.383","article-title":"Acetylcholine receptor turnover in mice with passively transferred myasthenia gravis. II. Receptor synthesis","volume":"46","author":"Wilson","year":"1983","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(18)50366-5","article-title":"Degradation of acetylcholine receptor in diaphragms of rats with experimental autoimmune myasthenia gravis","volume":"254","author":"Merlie","year":"1979","journal-title":"J Biol Chem"},{"key":"B34","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1002\/9780470720721.ch12","article-title":"Mechanisms of acetylcholine receptor loss from the neuromuscular junction","author":"Engel","year":"1982","journal-title":"Ciba Found Symp"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1923","article-title":"Complement: a key system for immune surveillance and homeostasis","volume":"11","author":"Ricklin","year":"2010","journal-title":"Nat Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.124388","article-title":"The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation","volume":"126","author":"Triantafilou","year":"2013","journal-title":"J Cell Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2004.08.002","article-title":"The role of complement in myasthenia gravis: serological evidence of complement consumption in vivo","volume":"158","author":"Romi","year":"2005","journal-title":"J Neuroimmunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21398","article-title":"Correlation of C3 level with severity of generalized myasthenia gravis","volume":"40","author":"Liu","year":"2009","journal-title":"Muscle Nerve"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1360","DOI":"10.3390\/biomedicines10061360","article-title":"Complement activation profile in myasthenia gravis patients: perspectives for tailoring anti-complement therapy","volume":"10","author":"Iacomino","year":"2022","journal-title":"Biomedicines"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/0303-8467(93)90103-n","article-title":"Soluble terminal complement components in human myasthenia gravis","volume":"95","author":"Barohn","year":"1993","journal-title":"Clin Neurol Neurosurg"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1991.tb03968.x","article-title":"Plasma C3c in immune-mediated neurological diseases: a preliminary report","volume":"83","author":"Kamolvarin","year":"1991","journal-title":"Acta Neurol Scand"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200057","article-title":"CD59 expression in skeletal muscles and its role in myasthenia gravis","volume":"10","author":"Iwasa","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1212\/wnl.39.10.1359","article-title":"Diagnostic significance of IgG, C3, and C9 at the limb muscle motor end-plate in minimal myasthenia gravis","volume":"39","author":"Tsujihata","year":"1989","journal-title":"Neurology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1987.tb51301.x","article-title":"The membrane attack complex of complement at the endplate in myasthenia gravis","volume":"505","author":"Engel","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-198003000-00005","article-title":"Ultrastructural localization of the terminal and lytic ninth complement component (C9) at the motor end-plate in myasthenia gravis","volume":"39","author":"Sahashi","year":"1980","journal-title":"J Neuropathol Exp Neurol"},{"key":"B46","first-page":"78","article-title":"Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates","volume":"5","author":"Fazekas","year":"1986","journal-title":"Clin Neuropathol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09498-4","article-title":"Role of complement and potential of complement inhibitors in myasthenia gravis and neuromyelitis optica spectrum disorders: a brief review","volume":"268","author":"Chamberlain","year":"2021","journal-title":"J Neurol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.42.7.595","article-title":"Immune complexes in myasthenia gravis","volume":"42","author":"Behan","year":"1979","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-022-02493-6","article-title":"Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities","volume":"144","author":"Rose","year":"2022","journal-title":"Acta Neuropathol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2023.1277596","article-title":"Role of complement in myasthenia gravis","volume":"14","author":"San","year":"2023","journal-title":"Front Neurol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s12974-016-0538-2","article-title":"Complement activation at the motor end-plates in amyotrophic lateral sclerosis","volume":"13","author":"Bahia El Idrissi","year":"2016","journal-title":"J Neuroinflammation"},{"key":"B52","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/bs.ai.2017.06.004","article-title":"Complement system in neural synapse elimination in development and disease","volume":"135","author":"Presumey","year":"2017","journal-title":"Adv Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2006.03198.x","article-title":"Complement membrane attack is required for endplate damage and clinical disease in passive experimental myasthenia gravis in Lewis rats","volume":"146","author":"Chamberlain-Banoub","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13083","article-title":"Development and characterization of novel anti-C5 monoclonal antibodies capable of inhibiting complement in multiple species","volume":"157","author":"Zelek","year":"2019","journal-title":"Immunology"},{"key":"B56","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/ana.21536","article-title":"Novel complement inhibitor limits severity of experimentally myasthenia gravis","volume":"65","author":"Soltys","year":"2009","journal-title":"Ann neurology"},{"key":"B57","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000524587","article-title":"Development, characterization, and in vivo validation of a humanized C6 monoclonal antibody that inhibits the membrane attack complex","volume":"15","author":"Gytz Olesen","year":"2023","journal-title":"J Innate Immun"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.612402","article-title":"Monoclonal antibodies capable of inhibiting complement downstream of C5 in multiple species","volume":"11","author":"Zelek","year":"2020","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"crossref","DOI":"10.4049\/jimmunol.140.8.2589","article-title":"C5 gene influences the development of murine myasthenia gravis","volume":"140","author":"Christadoss","year":"1988","journal-title":"J Immunol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/j.expneurol.2006.06.003","article-title":"Deficiency of decay accelerating factor and CD59 leads to crisis in experimental myasthenia","volume":"202","author":"Kaminski","year":"2006","journal-title":"Exp Neurol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.7.3847","article-title":"Genetic evidence for involvement of classical complement pathway in induction of experimental autoimmune myasthenia gravis","volume":"171","author":"T\u00fcz\u00fcn","year":"2003","journal-title":"J Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0195909","article-title":"Design and preclinical characterization of ALXN1210: A novel anti-C5 antibody with extended duration of action","volume":"13","author":"Sheridan","year":"2018","journal-title":"PloS One"},{"key":"B63","article-title":"Ravulizumab: first global approval","volume":"79","author":"McKeage","year":"2019","journal-title":"Drugs"},{"key":"B64","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1212\/WNL.0000000000204986","article-title":"Safety, efficacy, and patient preference for subcutaneous zilucoplan in myasthenia gravis after switching from intravenous complement component 5 inhibitors: an interim analysis of a phase 3b study (P10-11.006)","volume":"102","author":"Freimer","year":"2024","journal-title":"Neurology"},{"key":"B65","doi-asserted-by":"publisher","first-page":"EVIDoa2100066","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evid"},{"key":"B66","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1474-4422(23)00080-7","article-title":"Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"22","author":"Howard","year":"2023","journal-title":"Lancet Neurol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1016\/0090-1229(86)90085-1","article-title":"Interaction between immune complexes and C3b receptors on erythrocytes","volume":"39","author":"Yoshida","year":"1986","journal-title":"Clin Immunol Immunopathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.72.2.418","article-title":"A new complement function: solubilization of antigen-antibody aggregates","volume":"72","author":"Miller","year":"1975","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B69","article-title":"Complement-mediated inhibition of immune precipitation. I. Role of the classical and alternative pathways","volume":"47","author":"Schifferli","year":"1982","journal-title":"Clin Exp Immunol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(76)90787-x","article-title":"Multiple immune complexes and hypocomplementaemia in dermatitis herpetiformis and coeliac disease","volume":"1","author":"Mohammed","year":"1976","journal-title":"Lancet"},{"key":"B71","article-title":"Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations","volume":"52","author":"Engel","year":"1977","journal-title":"Mayo Clin Proc"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1097\/00005072-197803000-00008","article-title":"Ultrastructural localization of immune complexes (IgG and C3) at the end-plate in experimental autoimmune myasthenia gravis","volume":"37","author":"Sahashi","year":"1978","journal-title":"J Neuropathol Exp Neurol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200038","article-title":"Comparison of fixed and live cell-based assay for the detection of AChR and muSK antibodies in myasthenia gravis","volume":"10","author":"Spagni","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-020-02147-5","article-title":"Complement deposition at the neuromuscular junction in seronegative myasthenia gravis","volume":"139","author":"Hoffmann","year":"2020","journal-title":"Acta Neuropathol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2021-328665","article-title":"Eculizumab versus rituximab in generalised myasthenia gravis","volume":"93","author":"Nelke","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/CND.0000000000000388","article-title":"Minimal manifestations with eculizumab therapy in a patient with refractory generalized seropositive myasthenia gravis","volume":"23","author":"Abdulrazaq","year":"2022","journal-title":"J Clin Neuromuscul Dis"},{"key":"B77","doi-asserted-by":"publisher","first-page":"17562864241243186","DOI":"10.1177\/17562864241243186","article-title":"Long-term safety and efficacy of zilucoplan in patients with generalized myasthenia gravis: interim analysis of the RAISE-XT open-label extension study","volume":"17","author":"Howard","year":"2024","journal-title":"Ther Adv Neurol Disord"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0001051040.22359.0b","article-title":"Long-term corticosteroid treatment patterns and steroid-sparing effects of approved treatments for generalized myasthenia gravis in the United States","volume":"103","author":"Blackowicz","year":"2024","journal-title":"Neurology"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1378080\/full","article-title":"Ravulizumab use for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice","volume":"15","author":"Katyal","year":"2024","journal-title":"Front Neurol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3233\/JND-200584","article-title":"Clinical experience with eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized myasthenia gravis","volume":"8","author":"Katyal","year":"2021","journal-title":"J Neuromuscular Diseases"},{"key":"B81","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.nmd.2024.07.652","article-title":"510P Eculizumab versus rituximab for refractory anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: a single-center experience","volume":"43","author":"Durmus","year":"2024","journal-title":"Neuromuscular Disord"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2024-ABN.148","article-title":"Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: interim analysis of RAISE-XT","volume":"95","author":"Channa","year":"2024","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/bmjno-2024-ANZAN.35","article-title":"2997 Corticosteroid dose tapering in patients with generalised myasthenia gravis on zilucoplan: interim analysis of RAISE-XT","volume":"6","author":"Marchio","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"B84","article-title":"P.053 Concomitant corticosteroid use in ravulizumab-treated adults with anti-AChR antibody-positive gMG: results from the CHAMPION MG open-label extension","volume":"51","author":"Nicolle","year":"2024","journal-title":"Can J Neurological Sci"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.556104","article-title":"Concomitant immunosuppressive therapy use in eculizumab-treated adults with generalized myasthenia gravis during the REGAIN open-label extension study","volume":"11","author":"Nowak","year":"2020","journal-title":"Front Neurol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1080\/08916934.2016.1214823","article-title":"Effect of therapeutic plasma exchange on immunoglobulins in myasthenia gravis","volume":"49","author":"Guptill","year":"2016","journal-title":"Autoimmunity"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14500","article-title":"Changes in serum complements and their regulators in generalized myasthenia gravis","volume":"28","author":"Ozawa","year":"2021","journal-title":"Eur J Neurol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1436","article-title":"The contribution of the alternative pathway in complement activation on cell surfaces depends on the strength of classical pathway initiation","volume":"12","author":"de Boer","year":"2023","journal-title":"Clin Transl Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-023-07082-3","article-title":"Rituximab as a sole steroid-sparing agent in generalized myasthenia gravis: Long-term outcomes","volume":"45","author":"Kefalopoulou","year":"2024","journal-title":"Neurol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27521","article-title":"Autoantibody profile in myasthenia gravis patients with a refractory phase","volume":"65","author":"Veltsista","year":"2022","journal-title":"Muscle Nerve"},{"key":"B92","doi-asserted-by":"publisher","first-page":"104441.646","DOI":"10.1016\/j.nmd.2024.07.655","article-title":"513P Deposition of MAC and IgG subclasses at the neuromuscular junction in LRP4+ myasthenia gravis","volume":"43","author":"Hoffmann","year":"2024","journal-title":"Neuromuscular Disord"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213920","article-title":"Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation","volume":"14","author":"Tang","year":"2023","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.169135","article-title":"Eculizumab treatment alters the proteometabolome beyond the inhibition of complement","volume":"8","author":"Nelke","year":"2023","journal-title":"JCI Insight"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1756285617749134","DOI":"10.1177\/1756285617749134","article-title":"When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies","volume":"11","author":"Mantegazza","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"B96","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/CND.0000000000000034","article-title":"Treatment-refractory myasthenia gravis","volume":"15","author":"Silvestri","year":"2014","journal-title":"J Clin Neuromuscular Disease"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1756286419832242","DOI":"10.1177\/1756286419832242","article-title":"Understanding the burden of refractory myasthenia gravis","volume":"12","author":"Schneider-Gold","year":"2019","journal-title":"Ther Adv Neurol Disord"},{"key":"B98","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/mus.26114","article-title":"Burden of illness in patients with treatment refractory myasthenia gravis","volume":"58","author":"Engel-Nitz","year":"2018","journal-title":"Muscle Nerve"},{"key":"B99","article-title":"Use of serogroup B meningococcal vaccines in persons aged \u226510 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015","volume":"64","author":"Folaranmi","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B100","doi-asserted-by":"publisher","first-page":"577487","DOI":"10.1016\/j.jneuroim.2021.577487","article-title":"Complement C3 polymorphism is associated with the susceptibility of myasthenia gravis in Chinese adult patients","volume":"353","author":"Yue","year":"2021","journal-title":"J Neuroimmunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"893","DOI":"10.2353\/ajpath.2007.070240","article-title":"Myasthenia gravis thymus","volume":"171","author":"Leite","year":"2007","journal-title":"Am J Pathol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.6.1167","article-title":"Myasthenia gravis: quantitative immunocytochemical analysis of inflammatory cells and detection of complement membrane attack complex at the end-plate in 30 patients","volume":"43","author":"Nakano","year":"1993","journal-title":"Neurology"},{"key":"B103","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/mus.23448","article-title":"Cell surface complement regulators moderate experimental myasthenia gravis pathology","volume":"47","author":"Kusner","year":"2013","journal-title":"Muscle Nerve"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.05-1285","article-title":"Analysis of the Y402H variant of the complement factor H gene in age-related macular degeneration","volume":"47","author":"Baird","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2011.03.011","article-title":"Complement upregulation and activation on motor neurons and neuromuscular junction in the SOD1 G93A mouse model of familial amyotrophic lateral sclerosis","volume":"235","author":"Heurich","year":"2011","journal-title":"J Neuroimmunol"},{"key":"B106","doi-asserted-by":"publisher","first-page":"100077","DOI":"10.1016\/j.crneur.2023.100077","article-title":"The systemic inhibition of the terminal complement system reduces neuroinflammation but does not improve motor function in mouse models of CMT1A with overexpressed PMP22","volume":"4","author":"Michailidou","year":"2023","journal-title":"Curr Res Neurobiol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.5125","article-title":"Clinical effects of the self-administered subcutaneous complement inhibitor zilucoplan in patients with moderate to severe generalized myasthenia gravis: results of a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"77","author":"Howard","year":"2020","journal-title":"JAMA Neurology"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-023-11699-x","article-title":"Long-term efficacy and safety of ravulizumab in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: results from the phase 3 CHAMPION MG open-label extension","volume":"270","author":"Meisel","year":"2023","journal-title":"J Neurol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2591","DOI":"10.1212\/WNL.0000000000204620","article-title":"Long-term efficacy and safety of ravulizumab, a long-acting terminal complement inhibitor, in adults with anti-acetylcholine receptor antibody-positive generalized myasthenia gravis: final results from the phase 3 CHAMPION MG open-label extension (S15.010)","volume":"102","author":"Vu","year":"2024","journal-title":"Neurology"},{"key":"B110","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.pediatrneurol.2024.04.020","article-title":"Eculizumab in adolescent patients with refractory generalized myasthenia gravis: A phase 3, open-label, multicenter study","volume":"156","author":"Brandsema","year":"2024","journal-title":"Pediatr Neurol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","article-title":"Long-term safety and efficacy of eculizumab in generalized myasthenia gravis","volume":"60","author":"Muppidi","year":"2019","journal-title":"Muscle Nerve"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1526317\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T05:20:06Z","timestamp":1744694406000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1526317\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,15]]},"references-count":112,"alternative-id":["10.3389\/fimmu.2025.1526317"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1526317","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,15]]},"article-number":"1526317"}}